Holen Sie sich die Stockscreener-App
10.81
2.64%
-0.37
Schlusskurs vom Vortag:
$11.18
Offen:
$11.04
24-Stunden-Volumen:
585.64K
Relative Volume:
0.31
Marktkapitalisierung:
$1.83B
Einnahmen:
$68.56M
Nettoeinkommen (Verlust:
$-437.99M
KGV:
-3.4167
EPS:
-3.1639
Netto-Cashflow:
$-396.61M
1W Leistung:
-5.35%
1M Leistung:
+23.41%
6M Leistung:
+11.07%
1J Leistung:
+107.73%
1-Tages-Spanne:
$10.80
$11.38
1-Wochen-Bereich:
$10.86
$11.64
52-Wochen-Spanne:
$4.75
$11.94
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.81 | 1.89B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
522.64 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.89 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.62 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.08 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
How (VIR) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology stock gains on conference catalyst - AD HOC NEWS
Man Group plc Takes $1.54 Million Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology stock gains on new 52-week high and conference appearance - AD HOC NEWS
Corient Private Wealth LP Invests $3.17 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week HighShould You Buy? - MarketBeat
Vir Biotechnology stock gains on conference participation and 52-week high - ad-hoc-news.de
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week high at 11.66 USD - Investing.com
Vir Biotechnology (NASDAQ:VIR) Trading 4.8% HigherHere's What Happened - MarketBeat
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Business Wire
Deutsche Bank AG Acquires Shares of 134,258 Vir Biotechnology, Inc. $VIR - MarketBeat
ARCH Venture Management LLC Invests $129.35 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (NASDAQ: VIR) ex-officer lines up more sales - Stock Titan
Vir Biotechnology (NASDAQ:VIR) Shares Up 8.1%Time to Buy? - MarketBeat
Vir Biotechnology (NASDAQ: VIR) officer plans 14,352-share sale after 25K sale - Stock Titan
Vir Biotechnology (NASDAQ: VIR) ex-officer files notice for potential $245K stock sale - Stock Titan
Vir Biotechnology on Track for Record Winning Streak -- Data Talk - Bitget
Vir (VIR) Close and Levels: Adds 1.06% to Close at $9.49 in the Latest Reading; Key Levels: the $9.02 to $9.96 Range Remains in Focus in Latest TradingRevenue Weighted - vinanet.vn
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - Sahm
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum - TipRanks
Vir Biotechnology (VIR) Climbs 2.67% to $9.24 as Trading Volume Picks UpETH Profile - vinanet.vn
Vir Biotechnology Stock Price Forecast. Should You Buy VIR? - StockInvest.us
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo Finance
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund - Stock Titan
Equities Analysts Offer Predictions for VIR Q3 Earnings - marketbeat.com
Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028 - Pulse 2.0
Vir Biotechnology (NASDAQ:VIR): What’s Driving Fresh Attention? - Kalkine Media
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
H.C. Wainwright reiterates Vir Biotechnology stock rating on trial progress By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Vir Biotechnology stock rating on trial progress - Investing.com
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology (VIR) Receives a Buy from Bank of America Securities - The Globe and Mail
What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders - simplywall.st
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30 - Moomoo
Vir Biotechnology (VIR): State Street discloses 9.96M-share, 5.9% ownership position - Stock Titan
Understanding Momentum Shifts in (VIR) - Stock Traders Daily
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21, Implies 140% Upside - TradingView
Vir Biotechnology Inc (VIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vir Biotechnology, Inc. (VIR) Stock Analysis: Unpacking a 140% Potential Upside for Investors - DirectorsTalk Interviews
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.11, Implies 132% Upside - TradingView
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):